©The Author(s) 2026.
World J Gastrointest Endosc. Jan 16, 2026; 18(1): 113788
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.113788
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.113788
Table 2 Primary and secondary study outcomes, n (%)
| Outcomes | IND (n = 70) | LR (n = 70) | IND + LR (n = 70) | P value |
| PEP | 7 (10.00) | 12 (17.14) | 4 (5.71) | 1 |
| Severe PEP | 1 (1.4) | 2 (2.8) | 2 (2.8) | 0.86 |
| Pseudocyst | 1 (1.4) | 0 (0) | 0 (0) | 1.00 |
| Pulmonary edema | 1 (1.4) | 1 (1.4) | 0 (0) | 0.92 |
| Renal failure | 1 (1.4) | 1 (1.4) | 0 (0) | 0.93 |
| Gastrointestinal bleeding | 1 (1.4) | 2 (2.8) | 0 (0) | 0.82 |
| Anaphylaxis | 0 (0) | 0 (0) | 0 (0) | 0.98 |
| Death | 2 (2.8) | 1 (1.4) | 1 (1.4) | 1.00 |
| Readmission | 5 (7.14) | 7 (10) | 2 (2.8) | 1 |
| Mean length of stay, days | 3.40 | 4.70 | 3.12 | 0.12 |
- Citation: Amalou K, Benboudiaf N, Medkour MT, Belghanem F, Chetroub H, Rekab R, Belloula A, Bouaouina F, Saidani K. Lactated Ringer’s solution in combination with indomethacin for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized trial. World J Gastrointest Endosc 2026; 18(1): 113788
- URL: https://www.wjgnet.com/1948-5190/full/v18/i1/113788.htm
- DOI: https://dx.doi.org/10.4253/wjge.v18.i1.113788